Pancreatic adenocarcinoma is a cancer that forms in the cells lining the ducts of the pancreas. It accounts for roughly 95% of all pancreatic cancers, making it by far the most common type. It is also one of the most aggressive: the five-year survival rate remains among the lowest of any major cancer, largely because symptoms rarely appear until the disease has advanced.
Where It Starts
Your pancreas sits behind your stomach and has two main jobs: producing digestive enzymes (its exocrine function) and releasing hormones like insulin (its endocrine function). Pancreatic adenocarcinoma arises from the exocrine side, specifically from the cells that line the small ducts carrying digestive enzymes into the intestine.
For years, researchers assumed the cancer originated exclusively in these duct cells. More recent evidence shows that enzyme-producing cells called acinar cells can also transform into duct-like cells through a process called acinar-to-ductal metaplasia, then progress through a series of precancerous stages known as pancreatic intraepithelial neoplasias (PanINs). These precancerous lesions gradually accumulate genetic damage, shifting from mildly abnormal cells to increasingly disordered ones before becoming invasive cancer. Two other types of precancerous growths, called IPMNs and MCNs, can also eventually give rise to adenocarcinoma, though this path is less common.
The Genetic Mutations Driving Growth
Four key gene mutations appear again and again in pancreatic adenocarcinoma. The most important is KRAS, found in roughly 90 to 95% of tumors. KRAS acts like a stuck accelerator pedal: when mutated, it constantly signals the cell to grow and divide. This mutation occurs early, often already present in precancerous lesions.
The other three mutations disable the body’s braking systems. TP53, mutated in 50 to 77% of cases, normally stops damaged cells from multiplying. When it’s lost, cells with dangerous DNA errors keep dividing instead of self-destructing. SMAD4, inactivated in up to 60 to 90% of tumors, normally helps regulate cell growth and triggers programmed cell death. Its loss also weakens the immune response around the tumor by reducing the activity of cancer-killing immune cells. CDKN2A, altered in a large share of pancreatic tumors, controls a checkpoint in the cell division cycle. Together, these four mutations create a cell that grows unchecked, resists death signals, and evades immune surveillance.
Risk Factors
Smoking is the most well-established modifiable risk factor. Current smokers face roughly double the risk of developing pancreatic adenocarcinoma compared to nonsmokers. That risk climbs further with intensity and duration: people who smoke 30 or more cigarettes per day or who have smoked for 50 years or longer see their odds rise even higher.
Obesity also plays a meaningful role. A pooled analysis of 14 large studies involving more than 846,000 people found that obese individuals had a 47% higher risk compared to those at a healthy weight. For every five-point increase in BMI, pancreatic cancer risk rises by about 12%.
Chronic pancreatitis, or long-term inflammation of the pancreas, carries a particularly striking association. People diagnosed with chronic pancreatitis have roughly 8 to 16 times the risk of developing pancreatic adenocarcinoma in the years that follow, though the risk decreases over time. Type 2 diabetes is also linked to higher risk, and in some cases, new-onset diabetes in an older adult can itself be an early sign of a pancreatic tumor affecting insulin production.
Symptoms and Why They Appear Late
Pancreatic adenocarcinoma is notoriously silent in its early stages. The pancreas sits deep in the abdomen, and small tumors rarely press on surrounding structures enough to cause noticeable problems. By the time symptoms develop, the cancer has often grown substantially or spread.
The most common symptoms include abdominal pain that radiates to the back, unintentional weight loss, and loss of appetite. Jaundice, a yellowing of the skin and whites of the eyes, occurs when a tumor in the head of the pancreas blocks the bile duct. This can also cause dark urine, pale stools, and intense itching. Notably, jaundice from pancreatic cancer often appears without pain, which can delay people from seeking urgent evaluation. Weight loss happens partly because the cancer consumes more of the body’s energy and partly because digestive enzyme output drops, making it harder to absorb nutrients from food.
How It’s Diagnosed
Diagnosis typically begins with imaging. CT scans detect pancreatic adenocarcinoma with about 90% sensitivity and 87% specificity. MRI performs slightly better, with 93% sensitivity and 89% specificity. Endoscopic ultrasound (EUS), where a small ultrasound probe is passed through the mouth into the stomach, offers 91% sensitivity and can also obtain a tissue biopsy to confirm the diagnosis.
A blood marker called CA 19-9 is frequently measured during the workup. It has a sensitivity of about 79% and specificity of 82% for detecting pancreatic cancer. That means it misses roughly one in five cases and can be falsely elevated in other conditions like bile duct blockage or pancreatitis. CA 19-9 is more useful for tracking treatment response and detecting recurrence than as a standalone screening tool.
Treatment Based on Stage
Treatment depends heavily on whether the tumor can be surgically removed. Doctors categorize tumors into three broad groups: resectable (surgery is possible), borderline resectable (surgery may be possible after chemotherapy shrinks the tumor), and metastatic (cancer has spread to distant organs like the liver or lungs).
Surgery for Resectable Tumors
For tumors in the head of the pancreas, the standard operation is the Whipple procedure. This is a major surgery that removes the head of the pancreas, the duodenum, the gallbladder, the bile duct, and sometimes part of the stomach. The surgeon then reconnects the remaining pancreas, bile duct, and stomach to the small intestine so digestion can continue. A variation called the pylorus-preserving approach keeps the entire stomach intact.
Recovery involves a hospital stay during which drains placed during surgery are monitored for signs of a pancreatic leak. Once output is minimal and you can tolerate a regular diet, drains are removed. Most patients receive chemotherapy after surgery to reduce the chance of recurrence. Only about 15 to 20% of patients have tumors that are candidates for surgery at the time of diagnosis.
Chemotherapy for Advanced Disease
For metastatic pancreatic adenocarcinoma, two combination chemotherapy regimens are the current standard. FOLFIRINOX, a four-drug combination, showed a median survival of 11.1 months compared to 6.8 months with an older single-drug approach in clinical trials. A two-drug combination of gemcitabine plus nab-paclitaxel achieved a median survival of 8.7 months versus 6.6 months with gemcitabine alone. FOLFIRINOX tends to produce better outcomes but causes more side effects, so the choice between the two depends on a patient’s overall fitness and tolerance.
Why Immunotherapy Has Struggled
Immunotherapy has transformed treatment for many cancers, but pancreatic adenocarcinoma has proven largely resistant. Immune checkpoint inhibitors that work by releasing the brakes on the immune system have failed to improve outcomes in pancreatic cancer, with one narrow exception: the small fraction of patients whose tumors have a specific DNA repair deficiency called mismatch repair deficiency.
The reason lies in the tumor’s environment. Pancreatic adenocarcinoma surrounds itself with dense scar-like tissue that physically blocks immune cells from reaching the cancer. The loss of SMAD4 further weakens immune activity around the tumor. Researchers are exploring ways around this barrier, including engineered immune cells (CAR-T therapy) and vaccines that train the immune system to recognize KRAS mutations, but early clinical trials have shown limited success so far.
Targeted Therapies on the Horizon
KRAS was long considered “undruggable” because the protein’s surface lacked obvious spots where a drug could latch on. That changed with the development of drugs targeting a specific KRAS mutation called G12C. In a clinical trial of 38 pancreatic cancer patients with this mutation, one such drug achieved a response rate of 21%. Another drug targeting the same mutation produced responses in half of the 10 pancreatic cancer patients treated.
The limitation is that the G12C mutation is rare in pancreatic cancer. The most common KRAS mutations in pancreatic adenocarcinoma are G12D, G12V, and G12R. Newer drugs in development aim to block multiple KRAS variants at once, and early preclinical results show activity against these more common mutations. These broader inhibitors are now entering human trials, representing one of the most closely watched developments in pancreatic cancer research.